Baidu
map

Cell:科学家发现治疗肌萎缩症的基因新靶点

2015-11-16 生物通 生物通

最近,巴西圣保罗大学生物科学学院(IB-USP)和美国哈佛大学等处的研究人员发现,一个叫Jagged1(简称JAG1)的基因,可能是开发杜氏肌营养不良症(DMD)疗法的一个靶标,DMD是一种遗传性疾病,特征是渐进性肌肉退化。相关研究结果发表在十一月十二日的《Cell》杂志。 这项研究是在人类基因组和干细胞研究中心(HUG-CELL)完成的,由圣保罗研究基金(FAPESP)资助。HUG-CELL主

最近,巴西圣保罗大学生物科学学院(IB-USP)和美国哈佛大学等处的研究人员发现,一个叫Jagged1(简称JAG1)的基因,可能是开发杜氏肌营养不良症(DMD)疗法的一个靶标,DMD是一种遗传性疾病,特征是渐进性肌肉退化。相关研究结果发表在十一月十二日的《Cell》杂志。

这项研究是在人类基因组和干细胞研究中心(HUG-CELL)完成的,由圣保罗研究基金(FAPESP)资助。HUG-CELL主任、IB-USP遗传学教授Mayana Zatz指出:“到目前为止,所有的基因疗法试验都靶定肌营养不良蛋白的编码基因,但很少有成功的。我们提出了一种不同的方法,开辟了一系列新的可能性。”

Zatz解释说,杜氏肌营养不良症主要影响男性,是最常见和发展最快的肌营养不良症。它是由一个基因突变(通常是遗传性的)引起的,这个基因编码肌营养不良蛋白(dystrophin)——对于肌肉健康必不可少的一个蛋白,DMD患者完全没有这个蛋白。

Zatz说:“肌营养不良蛋白可保持肌肉细胞周围膜的完整性。当这种蛋白质缺失时,膜就变得松弛,所以重要的蛋白质就泄漏到肌肉组织外面,进入血液。相反,应保持在外面的物质,如钙,能够进入。”

杜氏肌营养不良症患者的心脏、膈膜和骨骼肌都受到影响。行走和奔跑的困难,第一次出现在5至3岁之间的男孩身上。患者寿命通常局限于10到12岁。Zatz说:“没有特别的照顾,患者活不到20岁。如今,有了辅助呼吸,他们可能活到40岁或更久。”

在过去的15年中,HUG-CELL的研究人员进行了实验,以扩大我们对于DMD的认识。他们研究了一些动物,例如出生时就具有一个dystrophin基因突变的黄金猎犬,它们表现出类似人类DMD的临床情况。大多数营养不良的狗只存活了两年或更少的时间。

Zatz说:“前一段时间,我们发现有一只狗,完全缺乏肌营养不良蛋白,但是却表现出较温和形式的疾病。它存活了11年,被认为是这一猎犬品种的正常年龄,并留下一只遗传该突变的后代,现在九岁。”

这两条狗分别命名为Ringo和Suflair,成为该研究小组关注的焦点,研究人员在健康狗、有严重肌肉萎缩症的狗,和上面两只具有温和疾病形式的狗当中,比较了它们的基因表达。

研究人员发现了一些候选基因,并与哈佛大学医学院的Louis Kunkel教授及其团队、麻省理工学院布罗德研究所的Kerstin Lindblad-Toh教授合作,将结果与遗传数据结合起来。他们在Ringo和Suflair中确定了一个基因组区域,与良性的临床条件有关,并发现这个区域中的一个基因——JAG1的表达增加。这可以解释为什么它们有更良性的疾病形式。

为了确认JAG1表达的改变能够影响疾病的严重性,Vieira用斑马鱼模型进行了实验。斑马鱼(Danio rerio)与人类共有约70%的基因组。实验是在Kunkel教授的实验室进行的。Kunkel教授发现了dystrophin基因,目前是哈佛医学院的研究员。

Zatz说:“斑马鱼模型也具有一个肌营养不良蛋白基因突变。其结果是,它的肌肉是虚弱的,它不能移动。当我们在没有肌营养不良蛋白的斑马鱼中增加JAG1的表达时,我们发现,75%的动物没有表现出营养不良的表型。”超表达是通过将JAG1信使RNA注入胚胎而被诱导的。

原文出处:

Natassia M. Vieira, Ingegerd Elvers,et al.Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype.cell.2015


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869243, encodeId=5a7c186924326, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 19 03:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802295, encodeId=c26618022952b, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue May 03 14:50:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695765, encodeId=f3c51695e6555, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 16 22:50:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959499, encodeId=be4b1959499ee, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 30 14:50:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288160, encodeId=88261288160c3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503059, encodeId=22c01503059a5, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43270, encodeId=fa39432e08b, content=进入临床还早, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:39:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869243, encodeId=5a7c186924326, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 19 03:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802295, encodeId=c26618022952b, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue May 03 14:50:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695765, encodeId=f3c51695e6555, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 16 22:50:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959499, encodeId=be4b1959499ee, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 30 14:50:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288160, encodeId=88261288160c3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503059, encodeId=22c01503059a5, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43270, encodeId=fa39432e08b, content=进入临床还早, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:39:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869243, encodeId=5a7c186924326, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 19 03:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802295, encodeId=c26618022952b, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue May 03 14:50:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695765, encodeId=f3c51695e6555, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 16 22:50:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959499, encodeId=be4b1959499ee, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 30 14:50:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288160, encodeId=88261288160c3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503059, encodeId=22c01503059a5, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43270, encodeId=fa39432e08b, content=进入临床还早, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:39:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869243, encodeId=5a7c186924326, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 19 03:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802295, encodeId=c26618022952b, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue May 03 14:50:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695765, encodeId=f3c51695e6555, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 16 22:50:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959499, encodeId=be4b1959499ee, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 30 14:50:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288160, encodeId=88261288160c3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503059, encodeId=22c01503059a5, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43270, encodeId=fa39432e08b, content=进入临床还早, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:39:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
    2015-12-30 智智灵药
  5. [GetPortalCommentsPageByObjectIdResponse(id=1869243, encodeId=5a7c186924326, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 19 03:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802295, encodeId=c26618022952b, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue May 03 14:50:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695765, encodeId=f3c51695e6555, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 16 22:50:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959499, encodeId=be4b1959499ee, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 30 14:50:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288160, encodeId=88261288160c3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503059, encodeId=22c01503059a5, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43270, encodeId=fa39432e08b, content=进入临床还早, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:39:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
    2015-11-18 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1869243, encodeId=5a7c186924326, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 19 03:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802295, encodeId=c26618022952b, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue May 03 14:50:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695765, encodeId=f3c51695e6555, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 16 22:50:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959499, encodeId=be4b1959499ee, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 30 14:50:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288160, encodeId=88261288160c3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503059, encodeId=22c01503059a5, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43270, encodeId=fa39432e08b, content=进入临床还早, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:39:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1869243, encodeId=5a7c186924326, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 19 03:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802295, encodeId=c26618022952b, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue May 03 14:50:00 CST 2016, time=2016-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695765, encodeId=f3c51695e6555, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Aug 16 22:50:00 CST 2016, time=2016-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959499, encodeId=be4b1959499ee, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 30 14:50:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288160, encodeId=88261288160c3, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503059, encodeId=22c01503059a5, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed Nov 18 04:50:00 CST 2015, time=2015-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43270, encodeId=fa39432e08b, content=进入临床还早, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:39:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
    2015-11-16 lixh1719

    进入临床还早

    0

相关资讯

Nat Neurosci:少突胶质细胞参与肌萎缩侧索硬化的发病过程

2013年3月31日-霍普金斯科学家称他们根据来自动物研究的证据证明一种中枢神经系统细胞而不是运动神经元在肌萎缩侧索硬化-一种致命性疾病-中扮演基本的角色。他们称,该研究有希望识别新的阻断该疾病进程的靶目标。自然神经科学在线的一项研究中发现,基因变异的小鼠繁殖导致了肌萎缩侧索硬化,少突胶质细胞-造成中枢神经系统神经绝缘的细胞-发生了巨大的变化-远在第一次疾病体征之前出现。少突胶质细胞位于运动神经元

Neurology:戊肝病毒或与神经痛性肌萎缩有关

神经痛性肌萎缩(NA)是一种原因不明的急性单相型臂丛神经紊乱疾病。目前认为NA的发病机制由多因素组成,大部分患者有前驱感染史。近年来,逐渐出现并增多的戊型肝炎(HEV)感染并发急性单相神经系统疾病的病例引起了广泛的关注。 NA患者常伴不明原因的肝功能轻度异常,但这些患者未针对性做过戊肝病毒的检测。因此来自荷兰内梅亨大学医学中心神经内科的Jeroen J.J. van Eijk博士等学者进

Baidu
map
Baidu
map
Baidu
map